Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases, including MET and VEGFR2. In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. Our studies aimed to determine the expression of cabozantinib targets...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nguyen, Holly M., Ruppender, Nazanin, Zhang, Xiaotun, Brown, Lisha G., Gross, Ted S., Morrissey, Colm, Gulati, Roman, Vessella, Robert L., Schimmoller, Frauke, Aftab, Dana T., Corey, Eva
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3808282/
https://ncbi.nlm.nih.gov/pubmed/24205338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0078881
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados